Tianjin Hengyu Medical Secures Over RMB 100 Million in New Funding to Advance Integrated Intravascular Imaging and Therapy Platform

Apr 22, 2026 17:32 CST Updated 17:32

Horimed

OCT Imaging Equipment R&D and Manufacturer

Instrument Family

Medical Device Media Reporting Pioneer

Share Professional Medical Device Knowledge

Source: Star Bridge Capital

"The Star Bridge Capital team demonstrated strong professional knowledge and coordination skills during this financing process, helping Horimed successfully complete the financing. We look forward to both parties continuing to work together for mutual benefit in the future!"

— HorimedFounders of Horimed: Liu Zhiyong, Zhao Shiyong

Recently, Horimed Technology Co., Ltd. (hereinafter referred to as“Horimed”) announced the completion of a financing round exceeding 100 million yuan. This round was led by CICC Capital and Xichuang Investment, with existing shareholder Chengdu Sci-Tech Investment adding to their investment. Starbridge Capital served as the long-term exclusive financial advisor. This marks another significant development for Horimed in2026An important financing completed at the beginning of the year will help the company further accelerate the research and development, production, and commercialization process of vascular interventional endoluminal imaging and treatment-related products.

Value Core: Building a Three-dimensional Integrated Platform for Diagnosis and Treatment in China with a Scarce "Intravascular Imaging + Cardiac Ultrasound System All-in-One Machine + Laser Ablation".

Horimed has been deeply engaged in the vascular intervention field, committed to building a technology and product system covering the entire process of precision diagnosis and treatment through continuous innovation. Focusing on the two core directions of intravascular ultrasound (IVUS) and optical coherence tomography (OCT), the company has formed a full-chain layout from core components, complete equipment to system solutions after years of accumulation. Relying on the mastery of both IVUS and OCT core technologies, the company continues to promote the coordinated development of the "dual technology routes," strengthening its comprehensive competitiveness in the field of precise diagnosis and treatment for vascular intervention. In addition, Horimed's self-developed 2D ICE and 4D ICE, as well as the all-in-one cardiac ultrasound system, have been proceeding steadily, and the significant laser product line is also being continuously improved, further solidifying the platform-based layout.

Market Opportunities: AI Empowers Smart Healthcare, the Era of Precision Medicine Has Arrived

With the deepening of the concept of precision medicine and the increasing demand for surgical standardization, the need for real-time, precise imaging navigation during vascular interventional procedures is growing rapidly. China has a large population of cardiovascular disease patients, and the number of coronary intervention surgeries performed annually continues to rise. At the same time, the penetration rate of intravascular imaging technology still lags behind that of developed countries, representing a significant market potential and growth opportunity. As clinical guidelines increasingly recommend intravascular imaging technologies and their wider adoption, China's intravascular imaging market is about to enter a period of rapid growth.Horimed, with its comprehensive product layout and technical accumulation in the AI-powered smart medical field, has built an integrated solution that combines image acquisition, intelligent analysis, and surgical guidance, fully preparing itself for the explosion of the AI precision healthcare market.

Strategic Upgrade: Expanding from Cardiovascular to Pan-Vascular Ecosystem

Horimed is undergoing a strategic upgrade from being a "cardiovascular expert" to becoming a "pan-vascular platform." Behind this transformation lies Horimed's deep insight and forward-looking layout in the vascular disease diagnosis and treatment market. Based on thorough market analysis and technology evaluation, Horimed has expanded its product portfolio to include cerebral OCT, carotid OCT, peripheral IVUS, and an OCT+IVUS+NIRS multimodal imaging system. In terms of cardiac ultrasound systems, the 2D ICE system has entered the registration phase; the 4D ICE (industry-leading ASIC+PZT electronic matrix mode) is set to enter the registration phase by the end of 2026; the integrated ICE+TTE+TEE cardiac ultrasound machine will also enter the registration phase in 2026. Notably, 4D ultrasound systems offer significant advantages over 2D ultrasound products in three-dimensional spatial imaging, real-time dynamic display, precise positioning analysis, and surgical navigation. Regarding laser ablation systems, the all-solid-state tunable UV laser system is currently under development and has completed multiple phantom experiments and live animal trials, with results demonstrating clear technical superiority.

This ecological expansion is attributed to Horimed's solid foundation in underlying technologies and the team’s continuous self-iteration capabilities. The cross-field expansion of indications not only reduces the risks associated with technology development but also opens up vast growth opportunities for Horimed to further expand its business landscape.

A relevant person in charge of CICC Capital stated: This investment in Horimed is a key step for CICC Capital’s strategic layout in China’s vascular intervention field. We highly value the company's independent innovation in products like IVUS and OCT, breaking the overseas monopoly. As a leading enterprise in China’s vascular interventional endovascular imaging field, Horimed has deeply cultivated the precision diagnosis and treatment track for pan-vascular diseases, with independent innovation as its core driving force. It has built a full-chain technical barrier from core components to complete equipment systems, playing a crucial role in promoting the import substitution and clinical popularization of high-end medical devices produced in China.

A relevant person in charge of Xichuang Investment stated: Intravascular interventional endoluminal imaging technology is the ‘eye’ for achieving precise PCI surgery, with great market potential and a clear demand for localization. We are optimistic about Horimed's technical strength in the optical and ultrasound fields and its unique advantage of a 'dual-technology approach' running in parallel. The company’s team not only possesses excellent R&D and innovation capabilities but also demonstrates highly efficient commercial execution. We believe that Horimed will continue to enhance its innovative product portfolio, accelerate the localization process, and provide more comprehensive and precise integrated diagnostic and treatment solutions for cardiovascular-related clinical needs.

A relevant official from Chengdu KCT stated: This investment in Horimed is an important part of Chengdu KCT Group's layout in intravascular interventional endoluminal imaging. We are optimistic about the company’s strong technical foundation in the cardiovascular field and its deep insights and forward-looking arrangements for the vascular disease diagnosis and treatment market. We look forward to future collaborative cooperation between both parties, further promoting the improvement and upgrading of related industrial chains in Chengdu.

Zou Feng, head of Xingqiao Capital, stated: Horimed has successfully completed a financing round exceeding 100 million yuan, fully demonstrating the capital market's high recognition of the company's technical strength, product portfolio, and industrialization capabilities. The company is deeply committed to the precision diagnosis and treatment track of pan-vascular interventions, continuously advancing its platform-based layout around IVUS, OCT, ICE, and laser technologies, with clear technical advantages and a well-defined growth trajectory. We are honored to have accompanied the company in completing this round of financing and look forward to Horimed achieving continuous breakthroughs in future developments.

END

GE Healthcare Global CEO Bets on Tianjin Again

A Century-Old Medical Device Giant: "China's First" Lands in Shanghai

Minimally Invasive’s Bet: Surgical Robotics Company Completes Major Acquisition

Siemens Announces: Timeline for Healthcare Business Spin-off

Well-known Innovative Medical Device Company, Layoffs 16%

Beijing High-End Vascular Intervention Company Completes 200 Million Yuan Financing

For the First Time, Mindray Adjusts Its Business Segments

Global Dental "Top Player" Undergoes Major Management Overhaul

750 Million, China's Leading Imaging Company Plans to Acquire

A New Era in Surgery Has Arrived, United Imaging Breaks Through with an Ecosystem

BusinessBusiness cooperation email: qxzj@landianyiliao.com